A ‘Global Reference’ Comparator for Biosimilar Development Christopher J. WebsterGillian R. Woollett Current Opinion Open access 19 May 2017 Pages: 279 - 286
Erratum to: A ‘Global Reference’ Comparator for Biosimilar Development Christopher J. WebsterGillian R. Woollett Erratum 02 August 2017 Pages: 287 - 287
Targeting Sclerostin in Postmenopausal Osteoporosis: Focus on Romosozumab and Blosozumab Ian R. Reid Leading Article 25 May 2017 Pages: 289 - 297
Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review Vibeke StrandAlejandro BalsaLisa Marshall Systematic Review Open access 13 June 2017 Pages: 299 - 316
Adeno-Associated Virus (AAV) as a Vector for Gene Therapy Michael F. NasoBrian TomkowiczWilliam R. Strohl Review Article Open access 01 July 2017 Pages: 317 - 334
Cell-Based Therapies with T Regulatory Cells Mateusz GliwińskiDorota Iwaszkiewicz-GrześPiotr Trzonkowski Review Article Open access 24 May 2017 Pages: 335 - 347
LBEC0101, A Proposed Etanercept Biosimilar: Pharmacokinetics, Immunogenicity, and Tolerability Profiles Compared with a Reference Biologic Product in Healthy Male Subjects Heechan LeeHyewon ChungKyung-Sang Yu Original Research Article 27 May 2017 Pages: 349 - 355
Efficacy, Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar CT-P10 Versus Innovator Rituximab in Patients with Rheumatoid Arthritis: Results up to Week 72 of a Phase I Randomized Controlled Trial Dae Hyun YooChang-Hee SuhWon Park Original Research Article Open access 13 June 2017 Pages: 357 - 367
Efficacy and Safety of Switching from Innovator Rituximab to Biosimilar CT-P10 Compared with Continued Treatment with CT-P10: Results of a 56-Week Open-Label Study in Patients with Rheumatoid Arthritis Won ParkChang-Hee SuhDae Hyun Yoo Original Research Article Open access 09 June 2017 Pages: 369 - 377
